Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 12.24 -0.60 (-4.67%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 11, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Travere Therapeutics Inc < Previous 1 2 3 Next > Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 13, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023 April 01, 2023 FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences March 28, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023 March 23, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 14, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023 March 14, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares March 03, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants February 28, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Proposed Public Offering of Common Stock February 27, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results February 23, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy February 17, 2023 From Ligand Pharmaceuticals Incorporated Via Business Wire Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy February 17, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results February 16, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) February 13, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences February 08, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) January 12, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Provides Corporate Update and 2023 Outlook January 09, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference January 03, 2023 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) December 14, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) November 16, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease November 15, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences November 09, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Third Quarter 2022 Financial Results October 27, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022 October 26, 2022 Data support the Company’s lead investigational product candidate sparsentan From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report Third Quarter 2022 Financial Results October 20, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy October 13, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) October 11, 2022 From Travere Therapeutics, Inc. Via GlobeNewswire Vifor Pharma and Travere Therapeutics announce licensing agreement for the commercialization of sparsentan in Europe, Australia and New Zealand September 16, 2021 From Vifor Pharma Group Via Business Wire < Previous 1 2 3 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.